Long Focus Capital Management LLC Increases Stock Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 54.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,494,393 shares of the biotechnology company's stock after buying an additional 7,194,503 shares during the quarter. Long Focus Capital Management LLC owned approximately 8.01% of Adaptimmune Therapeutics worth $11,040,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock valued at $1,361,000 after acquiring an additional 869,949 shares during the period. Rock Springs Capital Management LP grew its holdings in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 58,000 shares during the period. LPL Financial LLC increased its position in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buying an additional 94,623 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after buying an additional 98,581 shares during the period. Finally, Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after buying an additional 21,688 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company's stock.

Analyst Ratings Changes

ADAP has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a report on Friday, March 21st. Scotiabank lowered their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday, March 21st. StockNews.com initiated coverage on Adaptimmune Therapeutics in a research note on Tuesday. They set a "buy" rating for the company. Jones Trading downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Finally, Guggenheim dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1.83.

Adaptimmune Therapeutics Price Performance

NASDAQ:ADAP opened at $0.26 on Wednesday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.57. The stock has a market cap of $67.47 million, a PE ratio of -1.19 and a beta of 2.84. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics plc has a one year low of $0.20 and a one year high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million for the quarter, compared to analysts' expectations of $16.56 million. Equities research analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.